Insulet Corp. logo
PODDInsulet Corp.

Average EV/EBIT Ratio

EV/EBIT Ratio

The today ev/ebit ratio is 21.53x as of Thursday, June 25, 2026, shown against its trailing averages.

PODD EV/EBIT Ratio

PODD Average EV/EBIT Ratio

PODD EV/EBIT Ratio Averages

EV/EBIT RATIO TODAY

21.53x

EV/EBIT RATIO TTM

45.57x

EV/EBIT RATIO 3Y

59.31x

EV/EBIT RATIO 5Y

138.52x

EV/EBIT RATIO 10Y

N/A

EV/EBIT RATIO 15Y

N/A

EV/EBIT RATIO 20Y

N/A

About Insulet Corp.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Acton, MA
5,400 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Ashley A. McEvoy